Search This Blog

Monday, June 29, 2026

Abivax positive Phase 3 ABTECT Maintenance Part 2 for obefazimod in refractory ulcerative colitis

 

Abivax reports positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis

  • Results strengthen obefazimod's long-term safety profile in maintenance treatment of refractory ulcerative colitis patients
  • Data support planned Q4 2026 New Drug Application submission for obefazimod in the U.S.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)